Preliminary data suggest that a tumor-infiltrating lymphocyte therapy called LN-145 may provide an option for patients with non–small cell lung cancer whose disease has progressed despite receiving other therapies, including PD-1 or PD-L1checkpoint inhibitors. Trial participants had an overall response rate of 21.4%, and the median duration of response had not been reached after 8.2 months of follow-up.

You do not currently have access to this content.